Abstract
The small GTPase RhoA and its downstream effector, Rho kinase (ROCK), appear to mediate numerous pathophysiological signals, including smooth muscle cell contraction, actin cytoskeleton organization, cell adhesion and motility, proliferation, differentiation and the expression of several genes. Clinical interest in the RhoA/ROCK pathway has increased, due to emerging evidence that this signaling pathway is involved in the pathogenesis of several diseases, including hypertension, coronary vasospasm, stroke, atherosclerosis, heart failure and diabetes; ROCK is considered an important future therapeutic target. Several pharmaceutical companies are already actively engaged in the development of ROCK inhibitors as the next generation of therapeutic agents for these diseases. This review discusses the relationship between diabetes and hyperglycemia-induced RhoA/ROCK activation, highlights recent findings on the roles of ROCK inhibitors from experimental models of diabetes and clinical studies in cardiovascular patients, and elucidates major challenges for developing more selective ROCK inhibitors. Accumulating evidence suggests the potential of ROCK inhibitors as therapeutic agents for diabetes and its complications.
Keywords: RhoA, Rho kinase, inhibitors, diabetes, complications, GTPase, hypertension, coronary vasospasm, stroke, atherosclerosis
Current Pharmaceutical Design
Title:Rho Kinase Inhibitors: Potential Treatments for Diabetes and Diabetic Complications
Volume: 18 Issue: 20
Author(s): Hong Zhou and Yong-jun Li
Affiliation:
Keywords: RhoA, Rho kinase, inhibitors, diabetes, complications, GTPase, hypertension, coronary vasospasm, stroke, atherosclerosis
Abstract: The small GTPase RhoA and its downstream effector, Rho kinase (ROCK), appear to mediate numerous pathophysiological signals, including smooth muscle cell contraction, actin cytoskeleton organization, cell adhesion and motility, proliferation, differentiation and the expression of several genes. Clinical interest in the RhoA/ROCK pathway has increased, due to emerging evidence that this signaling pathway is involved in the pathogenesis of several diseases, including hypertension, coronary vasospasm, stroke, atherosclerosis, heart failure and diabetes; ROCK is considered an important future therapeutic target. Several pharmaceutical companies are already actively engaged in the development of ROCK inhibitors as the next generation of therapeutic agents for these diseases. This review discusses the relationship between diabetes and hyperglycemia-induced RhoA/ROCK activation, highlights recent findings on the roles of ROCK inhibitors from experimental models of diabetes and clinical studies in cardiovascular patients, and elucidates major challenges for developing more selective ROCK inhibitors. Accumulating evidence suggests the potential of ROCK inhibitors as therapeutic agents for diabetes and its complications.
Export Options
About this article
Cite this article as:
Zhou Hong and Li Yong-jun, Rho Kinase Inhibitors: Potential Treatments for Diabetes and Diabetic Complications, Current Pharmaceutical Design 2012; 18 (20) . https://dx.doi.org/10.2174/138161212800672688
DOI https://dx.doi.org/10.2174/138161212800672688 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Ivabradine: A Current Overview
Current Clinical Pharmacology Deciphering the Physiology Underlying the Rapid Clinical Effects of Perispinal Etanercept in Alzheimers Disease
Current Alzheimer Research Jak2 and Reactive Oxygen Species: A Complex Relationship
Current Chemical Biology Role of PPAR-γ Agonist Thiazolidinediones in Treatment of Pre-Diabetic and Diabetic Individuals: A Cardiovascular Perspective
Current Drug Targets - Cardiovascular & Hematological Disorders Is It Possible to Apply Secondary Stroke Prevention Guidelines to Very Old Populations?
Cardiovascular & Hematological Disorders-Drug Targets Heart Failure in Chronic Myocarditis: A Role for microRNAs?
Current Genomics Clinical Usefulness of N-terminal Prohormone of Brain Natriuretic Peptide and High Sensitivity Troponin T in Patients with Heart Failure Undergoing Cardiac Resynchronization Therapy
Current Pharmaceutical Design Urotensin II: A Vascular Mediator in Health and Disease
Current Vascular Pharmacology Silybin and Silymarin - New and Emerging Applications in Medicine
Current Medicinal Chemistry Long-Term Bronchodilator Inhaled Therapy in COPD: The Role of Tiotropium Bromidum
Reviews on Recent Clinical Trials Depsipeptide (FK228) as a Novel Histone Deacetylase Inhibitor: Mechanism of Action and Anticancer Activity
Mini-Reviews in Medicinal Chemistry Dissections of the Thoracic Aorta and Evolving Endovascular Strategies
Current Hypertension Reviews Drugs Targeting the Canonical NF-κB Pathway to Treat Viral and Autoimmune Myocarditis
Current Pharmaceutical Design Green Tea Polyphenols as an Anti-Oxidant and Anti-Inflammatory Agent for Cardiovascular Protection
Cardiovascular & Hematological Disorders-Drug Targets Evolving Concepts Concerning Cardiac β-Adrenoceptor Function in Heart Failure
Current Pharmaceutical Design Biomarkers of Atrial Fibrillation in Metabolic Syndrome
Current Medicinal Chemistry Synthetic Sustained Gene Delivery Systems
Current Topics in Medicinal Chemistry Effect of Mineralocorticoid Receptor Antagonists in Heart Failure with Preserved Ejection Fraction and with Reduced Ejection Fraction - A Narrative Review
Current Vascular Pharmacology Inflammatory Related Cardiovascular Diseases: From Molecular Mechanisms to Therapeutic Targets
Current Pharmaceutical Design New Technologies in Male Contraception
Current Women`s Health Reviews